Zidverc-Trajkovic J, Pekmezovic T, Jovanovic Z, Pavlovic A, Mijajlovic M, Radojicic A, Sternic N
Headache Centre, Institute of Neurology, Clinical Centre of Serbia, Belgrade, Serbia.
Cephalalgia. 2007 Nov;27(11):1219-25. doi: 10.1111/j.1468-2982.2007.01432.x. Epub 2007 Sep 21.
We present a prospective study of 240 patients with medication overuse headache (MOH) treated with drug withdrawal and prophylactic medications. At 1-year follow-up, 137 (57.1%) patients were without chronic headache and without medication overuse, eight (3.3%) patients did not improve after withdrawal and 95 (39.6%) relapsed developing recurrent overuse. Age at time of MOH diagnosis, regular use of benzodiazepines, frequency and Migraine Disability Assessment (MIDAS) score of chronic headache, age at onset of primary headache, frequency and MIDAS score of primary headache, ergotamine compound overuse and daily drug intake were significantly different between successfully and unsuccessfully treated patients. Multivariate analysis determined the frequency of primary headache disorder, ergotamine overuse and disability of chronic headache estimated by MIDAS as independent predictors of treatment efficacy at 1-year follow-up.
我们对240例药物过量使用性头痛(MOH)患者进行了一项前瞻性研究,这些患者接受了撤药及预防性药物治疗。在1年的随访中,137例(57.1%)患者无慢性头痛且无药物过量使用情况,8例(3.3%)患者撤药后未改善,95例(39.6%)复发并再次出现药物过量使用。成功治疗组与未成功治疗组患者在MOH诊断时的年龄、苯二氮䓬类药物的常规使用情况、慢性头痛的发作频率及偏头痛残疾评估(MIDAS)评分、原发性头痛的起病年龄、原发性头痛的发作频率及MIDAS评分、麦角胺类药物过量使用情况及每日药物摄入量方面存在显著差异。多因素分析确定原发性头痛疾病的发作频率、麦角胺过量使用情况以及由MIDAS评估的慢性头痛残疾程度为1年随访时治疗效果的独立预测因素。